U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895459) titled 'MRD Monitoring in Colorectal Cancer Using ctDNA' on Oct. 19.
Brief Summary: This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy. The objective is to detect minimal residual disease (MRD) early and to predict disease relapse or progression in patients with colorectal cancer (stages II-IV). By monitoring specific KRAS gene mutations (G12 and G13) using the ddPCR method, the study aims to improve risk stratification and treatment response monitoring following primary therapy.
Study Start Date: Feb. 07, 2023
Study Type: INTERVENTIONAL
Condition:
Colorecta...